IO Biotech (NASDAQ:IOBT - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect IO Biotech to post earnings of ($0.45) per share for the quarter.
IO Biotech Price Performance
IOBT traded up $0.01 on Friday, reaching $1.00. 67,413 shares of the stock were exchanged, compared to its average volume of 275,146. IO Biotech has a fifty-two week low of $0.66 and a fifty-two week high of $1.79. The company's 50-day moving average price is $0.95 and its 200 day moving average price is $0.94. The firm has a market capitalization of $65.88 million, a PE ratio of -0.73 and a beta of 0.09.
Analysts Set New Price Targets
IOBT has been the subject of a number of recent research reports. Piper Sandler upgraded IO Biotech to a "strong-buy" rating in a research note on Wednesday, March 12th. HC Wainwright reissued a "buy" rating and set a $12.00 target price on shares of IO Biotech in a research note on Tuesday, April 1st.
Check Out Our Latest Report on IO Biotech
About IO Biotech
(
Get Free Report)
IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
See Also
Before you consider IO Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IO Biotech wasn't on the list.
While IO Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
